(DHI) DR Horton - Overview
Stock: Homes, Townhomes, Mortgages, Rentals, Land
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.47% |
| Yield on Cost 5y | 2.16% |
| Yield CAGR 5y | 18.92% |
| Payout Consistency | 83.3% |
| Payout Ratio | 15.4% |
| Risk 5d forecast | |
|---|---|
| Volatility | 35.3% |
| Relative Tail Risk | -7.82% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.48 |
| Alpha | 3.95 |
| Character TTM | |
|---|---|
| Beta | 0.529 |
| Beta Downside | 0.160 |
| Drawdowns 3y | |
|---|---|
| Max DD | 41.28% |
| CAGR/Max DD | 0.43 |
Description: DHI DR Horton January 29, 2026
D.R. Horton (NYSE:DHI) is the largest homebuilder in the United States, developing and selling single-family detached homes, townhomes, duplexes, and residential lots across 126 markets in 36 states. Its business spans land acquisition, construction, mortgage financing, title services, and ancillary activities such as multi-family rentals, insurance operations, and ownership of water-related assets.
In fiscal 2025 the company reported $30.2 billion of revenue, a 7 % YoY increase, and net income of $2.5 billion, driven by a 5 % rise in average selling price to $382,000 and a 3 % lift in homebuilding starts to 85,000 units. The backlog at year-end stood at 78,000 homes, representing roughly 9 months of forward sales, while the debt-to-EBITDA ratio eased to 2.3×, down from 2.6× in 2024.
Key economic drivers remain the Federal Reserve’s policy stance and housing affordability. As of December 2025 the 30-year fixed mortgage rate averaged 5.9 %, up from 5.2 % a year earlier, which compresses demand but is partially offset by a modest rebound in the Housing Affordability Index (now 115, above the 2024 low of 102). Labor shortages in construction and rising material costs (lumber price index +12 % YoY) continue to pressure margins, while the broader homebuilding sector has outperformed the S&P 500, delivering a 9 % total return in 2025.
For a deeper quantitative dive, consult the ValueRay dashboard.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 3.34b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 1.88 > 1.0 |
| NWC/Revenue: 76.02% < 20% (prev 85.78%; Δ -9.76% < -1%) |
| CFO/TA 0.10 > 3% & CFO 3.63b > Net Income 3.34b |
| Net Debt (3.04b) to EBITDA (4.46b): 0.68 < 3 |
| Current Ratio: 6.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (293.3m) vs 12m ago -9.40% < -2% |
| Gross Margin: 23.27% > 18% (prev 0.26%; Δ 2301 % > 0.5%) |
| Asset Turnover: 96.24% > 50% (prev 104.7%; Δ -8.50% > 0%) |
| Interest Coverage Ratio: 139.3 > 6 (EBITDA TTM 4.46b / Interest Expense TTM 31.3m) |
Altman Z'' 10.00
| A: 0.74 (Total Current Assets 30.02b - Total Current Liabilities 4.54b) / Total Assets 34.64b |
| B: 0.91 (Retained Earnings 31.50b / Total Assets 34.64b) |
| C: 0.13 (EBIT TTM 4.36b / Avg Total Assets 34.83b) |
| D: 3.12 (Book Value of Equity 31.51b / Total Liabilities 10.08b) |
| Altman-Z'' Score: 11.91 = AAA |
Beneish M -1.44
| DSRI: 1.33 (Receivables 458.9m/377.8m, Revenue 33.52b/36.69b) |
| GMI: 1.11 (GM 23.27% / 25.73%) |
| AQI: 3.18 (AQ_t 0.12 / AQ_t-1 0.04) |
| SGI: 0.91 (Revenue 33.52b / 36.69b) |
| TATA: -0.01 (NI 3.34b - CFO 3.63b) / TA 34.64b) |
| Beneish M-Score: -1.44 (Cap -4..+1) = D |
What is the price of DHI shares?
Over the past week, the price has changed by +4.64%, over one month by +7.41%, over three months by +8.74% and over the past year by +21.43%.
Is DHI a buy, sell or hold?
- StrongBuy: 6
- Buy: 3
- Hold: 10
- Sell: 2
- StrongSell: 0
What are the forecasts/targets for the DHI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 160.5 | 2.7% |
| Analysts Target Price | 160.5 | 2.7% |
| ValueRay Target Price | 181 | 15.8% |
DHI Fundamental Data Overview February 09, 2026
P/E Forward = 14.3266
P/S = 1.3569
P/B = 1.8867
P/EG = 1.2549
Revenue TTM = 33.52b USD
EBIT TTM = 4.36b USD
EBITDA TTM = 4.46b USD
Long Term Debt = 5.55b USD (from longTermDebt, last quarter)
Short Term Debt = 829.0m USD (from shortTermDebt, last quarter)
Debt = 5.55b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.04b USD (from netDebt column, last quarter)
Enterprise Value = 48.53b USD (45.49b + Debt 5.55b - CCE 2.51b)
Interest Coverage Ratio = 139.3 (Ebit TTM 4.36b / Interest Expense TTM 31.3m)
EV/FCF = 13.96x (Enterprise Value 48.53b / FCF TTM 3.48b)
FCF Yield = 7.16% (FCF TTM 3.48b / Enterprise Value 48.53b)
FCF Margin = 10.37% (FCF TTM 3.48b / Revenue TTM 33.52b)
Net Margin = 9.95% (Net Income TTM 3.34b / Revenue TTM 33.52b)
Gross Margin = 23.27% ((Revenue TTM 33.52b - Cost of Revenue TTM 25.72b) / Revenue TTM)
Gross Margin QoQ = 23.16% (prev 21.67%)
Tobins Q-Ratio = 1.40 (Enterprise Value 48.53b / Total Assets 34.64b)
Interest Expense / Debt = 0.56% (Interest Expense 31.3m / Debt 5.55b)
Taxrate = 25.47% (203.3m / 798.1m)
NOPAT = 3.25b (EBIT 4.36b * (1 - 25.47%))
Current Ratio = 6.62 (Total Current Assets 30.02b / Total Current Liabilities 4.54b)
Debt / Equity = 0.23 (Debt 5.55b / totalStockholderEquity, last quarter 24.00b)
Debt / EBITDA = 0.68 (Net Debt 3.04b / EBITDA 4.46b)
Debt / FCF = 0.87 (Net Debt 3.04b / FCF TTM 3.48b)
Total Stockholder Equity = 24.14b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.57% (Net Income 3.34b / Total Assets 34.64b)
RoE = 13.81% (Net Income TTM 3.34b / Total Stockholder Equity 24.14b)
RoCE = 14.68% (EBIT 4.36b / Capital Employed (Equity 24.14b + L.T.Debt 5.55b))
RoIC = 10.67% (NOPAT 3.25b / Invested Capital 30.46b)
WACC = 7.05% (E(45.49b)/V(51.04b) * Re(7.86%) + D(5.55b)/V(51.04b) * Rd(0.56%) * (1-Tc(0.25)))
Discount Rate = 7.86% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -6.53%
[DCF Debug] Terminal Value 82.22% ; FCFF base≈3.23b ; Y1≈3.37b ; Y5≈3.88b
Fair Price DCF = 276.6 (EV 83.16b - Net Debt 3.04b = Equity 80.12b / Shares 289.7m; r=7.05% [WACC]; 5y FCF grow 4.56% → 2.90% )
EPS Correlation: -57.15 | EPS CAGR: -16.71% | SUE: 0.26 | # QB: 0
Revenue Correlation: -5.91 | Revenue CAGR: -3.91% | SUE: 0.64 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.15 | Chg30d=-0.326 | Revisions Net=-11 | Analysts=14
EPS current Year (2026-09-30): EPS=10.55 | Chg30d=-0.846 | Revisions Net=-14 | Growth EPS=-8.8% | Growth Revenue=-0.7%
EPS next Year (2027-09-30): EPS=12.24 | Chg30d=-1.276 | Revisions Net=-12 | Growth EPS=+16.0% | Growth Revenue=+6.2%